Unique challenges of cystic fibrosis-related diabetes
Unique challenges of cystic fibrosis-related diabetes
Individuals with cystic fibrosis and pancreatic insufficiency have a gradual decline in insulin secretion over time, which results in an increase in the prevalence of diabetes with age; up to 50% of adults with cystic fibrosis aged over 35 years have diabetes. Cystic fibrosis‐related diabetes differs from Type 1 and Type 2 diabetes in several ways; there is a pattern of insulin deficiency with reduced and delayed insulin response to carbohydrates but a sparing of basal insulin that results in glucose abnormalities, which are frequently characterized by normal fasting glucose and postprandial hyperglycaemia. Insulin deficiency and hyperglycaemia, even at levels which do not reach the threshold for a diagnosis of diabetes, have an adverse impact on lung function and clinical status in people with cystic fibrosis. Although the risk of microvascular complications occurs as in other forms of diabetes, the main reason for treatment is to prevent deterioration in lung function and weight loss; treatment may therefore be required at an earlier stage than for other types of diabetes. Treatment is usually with insulin, but management needs to take into account all the other medical issues that arise in cystic fibrosis.
Bridges, N.
d8828c8c-7bff-4a9e-853d-9f843225d47e
Rowe, R.
77770418-ad08-4aba-9685-1e39484a0ae4
Holt, R.I.G.
d54202e1-fcf6-4a17-a320-9f32d7024393
Bridges, N.
d8828c8c-7bff-4a9e-853d-9f843225d47e
Rowe, R.
77770418-ad08-4aba-9685-1e39484a0ae4
Holt, R.I.G.
d54202e1-fcf6-4a17-a320-9f32d7024393
Bridges, N., Rowe, R. and Holt, R.I.G.
(2018)
Unique challenges of cystic fibrosis-related diabetes.
Diabetic Medicine.
(doi:10.1111/dme.13652).
Abstract
Individuals with cystic fibrosis and pancreatic insufficiency have a gradual decline in insulin secretion over time, which results in an increase in the prevalence of diabetes with age; up to 50% of adults with cystic fibrosis aged over 35 years have diabetes. Cystic fibrosis‐related diabetes differs from Type 1 and Type 2 diabetes in several ways; there is a pattern of insulin deficiency with reduced and delayed insulin response to carbohydrates but a sparing of basal insulin that results in glucose abnormalities, which are frequently characterized by normal fasting glucose and postprandial hyperglycaemia. Insulin deficiency and hyperglycaemia, even at levels which do not reach the threshold for a diagnosis of diabetes, have an adverse impact on lung function and clinical status in people with cystic fibrosis. Although the risk of microvascular complications occurs as in other forms of diabetes, the main reason for treatment is to prevent deterioration in lung function and weight loss; treatment may therefore be required at an earlier stage than for other types of diabetes. Treatment is usually with insulin, but management needs to take into account all the other medical issues that arise in cystic fibrosis.
Text
Accepted CFRD review for Diabetic Medicine revised version
- Accepted Manuscript
More information
Accepted/In Press date: 17 April 2018
e-pub ahead of print date: 23 April 2018
Identifiers
Local EPrints ID: 420993
URI: http://eprints.soton.ac.uk/id/eprint/420993
ISSN: 0742-3071
PURE UUID: 1ef035d7-fa93-436c-91fc-52b157c72a2c
Catalogue record
Date deposited: 21 May 2018 16:30
Last modified: 16 Mar 2024 06:39
Export record
Altmetrics
Contributors
Author:
N. Bridges
Author:
R. Rowe
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
